TECHNOLOGY & DATA MANAGEMENT


“While AI matching platforms are ecient tey are ar rom eing erect and human oversight is still a crucial element. Deutsch explains that Belong. Life’s Natural Language Processing engine as een trained or seven years and while most of the suggested trials are aroriate or atients sometimes tere is still a need or ne-tuning


regulated. Recently, the European Parliament released a mandate draft to ensure the human-centric and ethical development of AI in Europe. While it does not have healthcare- specific rles, it otlines the possible ftre of AI.


hile waiting for healthcarespecific


regulations, van Harten recommends establishing partnerships that demonstrate rigorous data safety standards and expertise in patient safety.


The future of AI AI has been moving into every possible industry, including healthcare and pharma. Earlier this year, Microsoft’s BioGPT tool demonstrated “human parity” in analysing biomedical research. etsch says AI was a very generic term si months ago, bt since the dawn of ChatGPT, people can feel its presence in their everyday lives. As such, people are more open-minded abot AI than before, and both patients and physicians are more welcoming of the technology. The TrialSearch AI tool was launched a couple of weeks ago and myTomorrows has  physicians on board to test the beta version. e are getting some alitative feedbac that this AI application is very practical and it’s


32 | Outsourcing In Clinical Trials


saving time,” van Harten says. hile AI matching platforms are efficient,


they are far from being perfect, and hman oversight is still a crucial element. etsch eplains that elong.ifes atral


angage rocessing engine has been trained for seven years, and while most of the suggested trials are appropriate for patients, sometimes there is still a need for finetning. According to etsch, the adoption of AI is at the same development stage as autonomous cars. It can drive atonomosly, bt yo have to be there and tae control of the wheel if it is required,” he adds. an arten believes physicians are at the


centre of decision-making and that they can correct AI when needed. “It’s just a clinical decision-making tool and not a clinical decision-maker,” he says. orobiof notes there is no replacement for the hman side in this process, bt instead, AI shold be viewed as sharing the worload.


arios AI applications are being tested for


several stages of conducting clinical trials. From using predictive analytics and AI to potentially bypassing animal testing, to digital twins allowing researchers to digitally replicate trial participants and observe them in two scenarios in real time, AI is here to stay.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72